Cross-Sector entity
JAMA Oncology is most often covered alongside American Association for Cancer Research (AACR), which appears in 3 of these 3 stories. The clearest coverage concentration is regulation: 2 of 3 stories, with the rest divided among 1 other category. JAMA Oncology appears in 3 tracked Cross-Sector stories from July 15, 2026.
3 verified stories tracked
Last mentioned: Jul 15, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
JAMA Oncology is most often covered alongside American Association for Cancer Research (AACR), which appears in 3 of these 3 stories. The clearest coverage concentration is regulation: 2 of 3 stories, with the rest divided among 1 other category. JAMA Oncology appears in 3 tracked Cross-Sector stories from July 15, 2026. The tracked stories average 6.3 original sources each.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering JAMA Oncology. Shared-story counts are live from our verified record — not editorial picks.
AACR Report Released
The American Association for Cancer Research publishes its report on cancer disparities research disruption, revealing 93% of surveyed researchers affected.
JAMA Oncology Publication
A study in JAMA Oncology details the cancellation of 181 NCI grants, bringing the issue to wider academic attention.
NCI Cancels 181 Grants
In the first half of 2025, the National Cancer Institute cancels 181 grants worth over $317 million, many focused on cancer disparities research.
Executive Order on Federal Grants
The Trump administration issues an executive order enabling freezes and cancellations of scientific research grants, particularly those related to diversity and equity.
Federal policy changes have disrupted the work of 93% of cancer disparities researchers, according to a new AACR survey. With 78% unable to apply for NIH grants and 59% of ongoing projects halted, progress on reducing cancer deaths among rural Americans and Black women is under threat.
The cancellation of 181 NCI grants totaling $317 million in early 2025 has stopped cancer disparity clinical trials in their tracks, according to an AACR report. The biotech and pharma pipelines face disruption as critical early-stage research evaporates.
Source: houstonpublicmedia.org · wyomingpublicmedia.org
Federal funding freezes have halted most cancer disparities research, with 78% of scientists locked out of grants. The AACR report reveals that 93% of researchers are affected, disrupting clinical trials and threatening health equity gains. Providers face a future without evidence-based interventions for populations with 18%–35% higher cancer mortality.
Source: wkms.org
